You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameChlorphentermine
Accession NumberDB01556
TypeSmall Molecule
GroupsIllicit, Withdrawn
DescriptionA sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)
Structure
Thumb
Synonyms
4-Chloro-a,a-dimethylbenzeneethanamine
4-Chloro-a,a-dimethylphenethylamine
a,a-Dimethyl-p-chlorophenethylamine
Chlorphenterminum
Clorfentermina
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ApsedonNot Available
DesopimonNot Available
LucofenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chlorphentermine hydrochloride
Thumb
  • InChI Key: WEJDYJKJPUPMLH-UHFFFAOYSA-N
  • Monoisotopic Mass: 219.058154899
  • Average Mass: 220.139
DBSALT000815
Categories
UNIINHW07912O7
CAS number461-78-9
WeightAverage: 183.678
Monoisotopic: 183.08147716
Chemical FormulaC10H14ClN
InChI KeyZCKAMNXUHHNZLN-UHFFFAOYSA-N
InChI
InChI=1S/C10H14ClN/c1-10(2,12)7-8-3-5-9(11)6-4-8/h3-6H,7,12H2,1-2H3
IUPAC Name
1-(4-chlorophenyl)-2-methylpropan-2-amine
SMILES
CC(C)(N)CC1=CC=C(Cl)C=C1
Pharmacology
IndicationUsed as an appetite suppressant.
Structured Indications Not Available
PharmacodynamicsChlorphentermine is a relatively weak stimulant with little abuse potential. It is no longer used due mainly to safety concerns, as it has a serotonergic effects profile similar to other withdrawn appetite suppressants such as fenfluramine and aminorex which were found to cause pulmonary hypertension and cardiac fibrosis following prolonged use.
Mechanism of action
Related Articles
AbsorptionWell absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life40 hours
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Chlorphentermine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Chlorphentermine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Chlorphentermine.Approved
AcrivastineChlorphentermine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineChlorphentermine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilChlorphentermine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineChlorphentermine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlphacetylmethadolChlorphentermine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Chlorphentermine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of Chlorphentermine.Approved
Ammonium chlorideThe serum concentration of Chlorphentermine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Chlorphentermine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Chlorphentermine.Approved, Illicit
AntazolineChlorphentermine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Chlorphentermine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Chlorphentermine.Approved
AstemizoleChlorphentermine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Chlorphentermine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Chlorphentermine.Vet Approved
AzatadineChlorphentermine may decrease the sedative activities of Azatadine.Approved
AzelastineChlorphentermine may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Chlorphentermine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Chlorphentermine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Chlorphentermine.Approved, Illicit
BezitramideChlorphentermine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Chlorphentermine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Chlorphentermine.Approved
BromperidolBromperidol may decrease the stimulatory activities of Chlorphentermine.Investigational
BrompheniramineChlorphentermine may decrease the sedative activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Bucindolol.Investigational
BuclizineChlorphentermine may decrease the sedative activities of Buclizine.Approved
BuprenorphineChlorphentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic AcidChlorphentermine may decrease the sedative activities of Butanoic Acid.Experimental
ButorphanolChlorphentermine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
CarbinoxamineChlorphentermine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilChlorphentermine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Chlorphentermine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Chlorphentermine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Celiprolol.Approved, Investigational
CetirizineChlorphentermine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineChlorphentermine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineChlorphentermine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineChlorphentermine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Chlorphentermine.Approved, Withdrawn
CimetidineChlorphentermine may decrease the sedative activities of Cimetidine.Approved
CinnarizineChlorphentermine may decrease the sedative activities of Cinnarizine.Approved
ClemastineChlorphentermine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Chlorphentermine.Approved, Vet Approved
ClomipramineClomipramine may increase the stimulatory activities of Chlorphentermine.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of Chlorphentermine.Approved
CodeineChlorphentermine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Chlorphentermine.Approved
CyclizineChlorphentermine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Chlorphentermine.Approved
CyproheptadineChlorphentermine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Chlorphentermine.Approved
DesipramineDesipramine may increase the stimulatory activities of Chlorphentermine.Approved
DesloratadineChlorphentermine may decrease the sedative activities of Desloratadine.Approved, Investigational
DexbrompheniramineChlorphentermine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleateChlorphentermine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideChlorphentermine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneChlorphentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineChlorphentermine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
DihydrocodeineChlorphentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineChlorphentermine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineChlorphentermine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateChlorphentermine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneChlorphentermine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineChlorphentermine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineChlorphentermine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateChlorphentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Chlorphentermine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Chlorphentermine.Approved
DosulepinDosulepin may increase the stimulatory activities of Chlorphentermine.Approved
DoxepinChlorphentermine may decrease the sedative activities of Doxepin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Doxofylline.Approved
DoxylamineChlorphentermine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEChlorphentermine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Chlorphentermine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
EbastineChlorphentermine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Chlorphentermine.Investigational
EmedastineChlorphentermine may decrease the sedative activities of Emedastine.Approved
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Chlorphentermine.Approved
EpinastineChlorphentermine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Chlorphentermine.Approved, Vet Approved
EsmirtazapineChlorphentermine may decrease the sedative activities of Esmirtazapine.Investigational
EthopropazineChlorphentermine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Chlorphentermine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Withdrawn
EthylmorphineChlorphentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Etilefrine.Withdrawn
EtorphineChlorphentermine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineChlorphentermine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Chlorphentermine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Chlorphentermine.Approved
FentanylChlorphentermine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineChlorphentermine may decrease the sedative activities of Fexofenadine.Approved
FlunarizineChlorphentermine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Chlorphentermine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Chlorphentermine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Chlorphentermine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Chlorphentermine.Approved, Vet Approved
GuanethidineThe serum concentration of Chlorphentermine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Chlorphentermine.Approved
HeroinChlorphentermine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of Chlorphentermine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of Chlorphentermine.Approved
HydrocodoneChlorphentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneChlorphentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Hydroxyamphetamine hydrobromide.Approved
HydroxyzineChlorphentermine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Chlorphentermine.Approved
ImipramineImipramine may increase the stimulatory activities of Chlorphentermine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Chlorphentermine.Approved
Ioflupane I-123Chlorphentermine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of Chlorphentermine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Chlorphentermine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Chlorphentermine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Chlorphentermine.Approved
IsothipendylChlorphentermine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Isoxsuprine.Approved, Withdrawn
Kct 0809Chlorphentermine may decrease the sedative activities of Kct 0809.Investigational
KetobemidoneChlorphentermine may increase the analgesic activities of Ketobemidone.Approved
KetotifenChlorphentermine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of Chlorphentermine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorphentermine.Approved
LevocabastineChlorphentermine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineChlorphentermine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateChlorphentermine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevorphanolChlorphentermine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Chlorphentermine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Chlorphentermine.Approved
LodoxamideChlorphentermine may decrease the sedative activities of Lodoxamide.Approved
LofentanilChlorphentermine may increase the analgesic activities of Lofentanil.Illicit
LoratadineChlorphentermine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Chlorphentermine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Chlorphentermine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Chlorphentermine.Withdrawn
MeclizineChlorphentermine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of Chlorphentermine.Approved
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Chlorphentermine.Approved
MepyramineChlorphentermine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineChlorphentermine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Chlorphentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Chlorphentermine.Approved, Investigational
MethadoneChlorphentermine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateChlorphentermine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Methamphetamine.Approved, Illicit
MethapyrileneChlorphentermine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Chlorphentermine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Chlorphentermine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Chlorphentermine.Investigational
MetiamideChlorphentermine may decrease the sedative activities of Metiamide.Experimental
MianserinChlorphentermine may decrease the sedative activities of Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Chlorphentermine.Approved
MinaprineMinaprine may increase the hypertensive activities of Chlorphentermine.Approved
MirtazapineChlorphentermine may decrease the sedative activities of Mirtazapine.Approved
MizolastineChlorphentermine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Chlorphentermine.Approved
MolindoneMolindone may decrease the stimulatory activities of Chlorphentermine.Approved
MorphineChlorphentermine may increase the analgesic activities of Morphine.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Chlorphentermine.Approved, Investigational
NalbuphineChlorphentermine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Chlorphentermine.Withdrawn
NizatidineChlorphentermine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Chlorphentermine.Approved
NormethadoneChlorphentermine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of Chlorphentermine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Chlorphentermine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Chlorphentermine.Approved, Investigational
OlopatadineChlorphentermine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Chlorphentermine.Approved
OpipramolOpipramol may increase the stimulatory activities of Chlorphentermine.Investigational
OpiumChlorphentermine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Chlorphentermine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Chlorphentermine.Investigational
OxycodoneChlorphentermine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Chlorphentermine.Approved
OxymorphoneChlorphentermine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of Chlorphentermine.Approved
PargylinePargyline may increase the hypertensive activities of Chlorphentermine.Approved
PemirolastChlorphentermine may decrease the sedative activities of Pemirolast.Approved
PentazocineChlorphentermine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Chlorphentermine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Chlorphentermine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Chlorphentermine.Approved
PethidineChlorphentermine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Chlorphentermine.Approved
PhenindamineChlorphentermine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Chlorphentermine.Withdrawn
PheniramineChlorphentermine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Chlorphentermine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Chlorphentermine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Chlorphentermine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Chlorphentermine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Chlorphentermine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Chlorphentermine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Chlorphentermine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Chlorphentermine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Chlorphentermine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Chlorphentermine.Approved
PiritramideChlorphentermine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Chlorphentermine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Chlorphentermine.Withdrawn
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Chlorphentermine.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
PromethazineChlorphentermine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Chlorphentermine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Chlorphentermine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Chlorphentermine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Chlorphentermine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Chlorphentermine.Investigational
RanitidineChlorphentermine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Chlorphentermine.Approved
RemifentanilChlorphentermine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Chlorphentermine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Chlorphentermine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Chlorphentermine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Chlorphentermine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Chlorphentermine.Approved
Roxatidine acetateChlorphentermine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Chlorphentermine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of Chlorphentermine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Chlorphentermine.Approved, Withdrawn
Spaglumic AcidChlorphentermine may decrease the sedative activities of Spaglumic Acid.Approved
SufentanilChlorphentermine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Chlorphentermine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Synephrine.Experimental
TapentadolChlorphentermine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Chlorphentermine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Chlorphentermine.Approved
TerfenadineChlorphentermine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneChlorphentermine may decrease the sedative activities of Tesmilifene.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Tetryzoline.Approved
ThioproperazineThioproperazine may decrease the stimulatory activities of Chlorphentermine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Chlorphentermine.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of Chlorphentermine.Approved
ThonzylamineChlorphentermine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Chlorphentermine.Approved
TiaprideTiapride may decrease the stimulatory activities of Chlorphentermine.Investigational
ToloxatoneToloxatone may increase the hypertensive activities of Chlorphentermine.Approved
TramadolChlorphentermine may increase the analgesic activities of Tramadol.Approved, Investigational
TranilastChlorphentermine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Chlorphentermine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Chlorphentermine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Chlorphentermine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of Chlorphentermine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of Chlorphentermine.Approved
TripelennamineChlorphentermine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineChlorphentermine may decrease the sedative activities of Triprolidine.Approved
TyramineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Tyramine.Investigational, Nutraceutical
Vitamin CThe serum concentration of Chlorphentermine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Chlorphentermine.Approved
ZotepineZotepine may decrease the stimulatory activities of Chlorphentermine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Chlorphentermine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. GYLYS JA, HART JJ, WARREN MR: Chlorphentermine, a new anorectic agent. J Pharmacol Exp Ther. 1962 Sep;137:365-73. [PubMed:13903304 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9792
Caco-2 permeable+0.7531
P-glycoprotein substrateNon-substrate0.6627
P-glycoprotein inhibitor INon-inhibitor0.9092
P-glycoprotein inhibitor IINon-inhibitor0.9805
Renal organic cation transporterNon-inhibitor0.8185
CYP450 2C9 substrateNon-substrate0.8464
CYP450 2D6 substrateSubstrate0.5148
CYP450 3A4 substrateNon-substrate0.5233
CYP450 1A2 substrateInhibitor0.6449
CYP450 2C9 inhibitorNon-inhibitor0.8526
CYP450 2D6 inhibitorInhibitor0.8286
CYP450 2C19 inhibitorNon-inhibitor0.752
CYP450 3A4 inhibitorNon-inhibitor0.5737
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.8728
CarcinogenicityNon-carcinogens0.6055
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.8974 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.738
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
boiling point100-102 °C at 2.00E+00 mm HgNot Available
logP2.60HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP2.81ALOGPS
logP2.69ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)10.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity53.15 m3·mol-1ChemAxon
Polarizability20.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:10 / Updated on August 17, 2016 12:23